Enliven Therapeutics annual shares outstanding
2019
2020
2021
2022
2023
2024
2025
Enliven Therapeutics Shares Outstanding History (ELVN)
Enliven Therapeutics reported 59.4M shares outstanding at the end of fiscal 2025.
View full Enliven Therapeutics company overviewEnliven Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 59.4M | 10.5M | +21.46% |
| 2024 | 2024-12-31 | 48.9M | 7.6M | +18.51% |
| 2023 | 2023-12-31 | 41.3M | 37.7M | +1056.63% |
| 2022 | 2022-12-31 | 3.6M | −22.7M | −86.42% |
| 2021 | 2021-12-31 | 26.3M | 8.7M | +49.80% |
| 2020 | 2020-12-31 | 17.5M | 16.8M | +2397.94% |
| 2019 | 2019-12-31 | 702,510 | — | — |
Enliven Therapeutics quarterly shares outstanding
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
As of Feb 23, 2023
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 73.3M | 14.0M | +23.68% |
| Q1 2026 | 2026-03-31 | 60.9M | 11.9M | +24.17% |
| Q4 2025 | 2025-12-31 | 59.4M | 10.5M | +21.46% |
| Q3 2025 | 2025-09-30 | 59.3M | 12.0M | +25.41% |
| Q2 2025 | 2025-06-30 | 59.2M | 12.1M | +25.55% |
| Q1 2025 | 2025-03-31 | 49.0M | 2.3M | +4.82% |
| Q4 2024 | 2024-12-31 | 48.9M | 7.6M | +18.51% |
| Q3 2024 | 2024-09-30 | 47.3M | 6.0M | +14.68% |
| Q2 2024 | 2024-06-30 | 47.2M | 6.0M | +14.63% |
| Q1 2024 | 2024-03-31 | 46.8M | 5.7M | +13.81% |
| Q4 2023 | 2023-12-31 | 41.3M | 280,526 | +0.68% |
| Q3 2023 | 2023-09-30 | 41.2M | 37.6M | +1054.19% |
| Q2 2023 | 2023-06-30 | 41.2M | 14.9M | +56.54% |
| Q1 2023 | 2023-03-31 | 41.1M | 14.8M | +56.37% |
| As of Feb 23, 2023 | 2023-02-23 | 41.0M | 14.7M | +56.01% |
| Q4 2022 | 2022-12-31 | 3.6M | −22.7M | −86.42% |
| Q3 2022 | 2022-09-30 | 26.3M | 11,542 | +0.04% |
| Q2 2022 | 2022-06-30 | 26.3M | 8.4M | +46.77% |
| Q1 2022 | 2022-03-31 | 26.3M | 8.7M | +49.22% |
| Q4 2021 | 2021-12-31 | 26.3M | 8.7M | +49.80% |
| Q3 2021 | 2021-09-30 | 26.3M | 8.9M | +51.21% |
| Q2 2021 | 2021-06-30 | 17.9M | 586,201 | +3.38% |
| Q1 2021 | 2021-03-31 | 17.6M | 1.0M | +6.28% |
| Q4 2020 | 2020-12-31 | 17.5M | 16.8M | +2397.94% |
| Q3 2020 | 2020-09-30 | 17.4M | — | — |
| Q2 2020 | 2020-06-30 | 17.3M | — | — |
| Q1 2020 | 2020-03-31 | 16.6M | — | — |
| Q4 2019 | 2019-12-31 | 702,510 | — | — |
Enliven Therapeutics shares outstanding trends
Over the last five reported fiscal years, Enliven Therapeutics's shares outstanding moved from 17.5M to 59.4M, a change of 41.9M. The latest reported quarter, Q2 2026, shows 73.3M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Enliven Therapeutics filings at SEC.gov ↗